Introduction
Survivin is an inhibitor of apoptosis protein (IAP), a conserved family of endogenous caspase inhibitors originally identified in baculovirus. Similar to other IAPs, Survivin blocks apoptosis by inhibiting caspase-3, -7 and -9 (Shin et al., 2001; Pennati et al., 2004) and antisense (AS) targeting of Survivin expression enhances apoptosis (Chen et al., 2000; Olie et al., 2000; McKay et al., 2003) . Survivin is regulated in a cell cycledependent manner, with maximal expression during G 2 / M phase, and is localized to mitotic spindle microtubules (Li et al., 1998) , suggesting regulation of both cell division and apoptosis. In most adult tissues, Survivin expression is repressed; however, it is prominently expressed in most cancers, and in some normal proliferating cells, including fetal tissue, T-lymphocytes and hematopoietic cells (Fukuda et al., 2002; Altieri, 2003) .
The tumor suppressor p53 can block cell cycle progression and/or induce apoptosis by transactivation of specific target genes, including p21
Waf-1/Cip1 , Gadd45, cyclin G and Bax (Chumakov, 2000; Fridman and Lowe 2003) . Survivin overexpression and loss of wild-type p53 expression/function are common events associated with neoplastic development, suggesting a functional link between Survivin and p53. Recently, repression of Survivin by wild-type p53 has been described (Hoffman et al., 2002) and loss of Survivin mediates, in part, the p53-dependent apoptotic pathway (Mirza et al., 2002) . However, these observations do not address or rule out reciprocal regulation of p53 by Survivin. Since p53 expression and function is regulated by Mdm2 (Haupt et al., 1997; Kubbutat et al., 1997) , which is a caspase substrate (Chen et al., 1997; Erhardt et al., 1997) , and Survivin blocks caspase activity, we investigated whether Survivin regulates p53. Herein, we demonstrate that Survivin regulates p53 expression and modifies p53 degradation through a caspase-3/Mdm2 axis. In addition, Survivin differentially regulates expression of the p53 homologues, p63 and p73, which may represent new molecular pathways in which Survivin participates.
Results

Ectopic Survivin expression blocks Adriamycin-induced apoptosis and provides BaF3 cells with a growth advantage
Survivin is overexpressed in cancers and may play a role in tumorigenesis and neoplastic cell growth by blocking apoptosis (Adida et al., 2000; Hayashibara et al., 2002) .
Forced expression of Survivin in IL-3-dependent BaF3 cells (Figure 1 , inset) does not impart growth factor independence, as previously reported (Ambrosini et al., 1997) , but significantly protects cells from Adriamycininduced apoptosis, as measured by reduced caspase-3 activation, reduced hypodiploid DNA content and lower Annexin-V expression. In contrast, disruption of Survivin protein by overexpression of T34A dominantnegative Survivin or an AS Survivin construct (Figure 1 , inset) promotes apoptosis (Table 1) .
To determine if the antiapoptotic effects of Survivin provide cells with proliferative advantages, BaF3 cells stably expressing various Survivin-IRES-GFP constructs were selected by FACS, admixed with untransduced GFP Negative cells in equal ratios and the percentages of GFP Positive cells followed over time (Figure 1 ). Survivin-transduced cells displayed a significant growth advantage compared to vector controltransduced cells, reaching 2.5 : 1 after 7 weeks, while Survivin disruption resulted in a progressive growth disadvantage.
Survivin inhibits pan-p53 and phosphor-Ser
-p53 accumulation induced by Adriamycin
Since Survivin overexpression and loss of wild-type p53 function are found in most cancers, we investigated whether Survivin regulates p53 expression. In BaF3 cells, which express wild-type p53 (Goetz et al., 2001) , Survivin overexpression had little effect on p53 levels compared to vector control cells at early time points, which is not unexpected in cells maximally stimulated by cytokine. However, p53 levels were consistently lower at later time points, particularly 8-24 h following Adriamycin treatment (Figure 2a ). Cells expressing T34A and AS Survivin showed significantly higher p53 protein at all time points tested compared to controls. A similar reduction in Ser 15 -phosphorylated p53 was observed in Survivin-transduced cells 24 h after Adriamycin treatment, while enhanced phospho-Ser 15 -p53 levels were observed in T34A-and AS-Survivin-expressing cells (Figure 2b) .
We extended this analysis to nonhematopoietic cells and utilized transient transfection of Survivin constructs in MCF7 cells that express wild-type p53 (Blagosklonny et al., 1995) , to rule out possible effects due to selection using stably transduced cells. We routinely observed efficient levels of protein expression of wild-type and T34A Survivin in MCF7 cells and strong reduction in endogenous Survivin in cells transfected with AS Survivin (Figure 3a) . After the 18-h transfection period, ectopic Survivin had little effect on total and phosphoSer 15 -p53 protein; however, Survivin disruption by either T34A or AS Survivin resulted in significant elevation of total and phospho-Ser 15 -p53 (Figure 3a ). Similar to BaF3 cells, transient overexpression of Survivin blocked the increase in total and phospho-Ser 15 -p53 protein induced by Adriamycin treatment for 6 h, while the DNA damage-induced increase in p53 protein was amplified in cells expressing T34A or AS Survivin. Parallel changes in mRNA for the p53-regulated gene Gadd45 and p21 WAFÀ1/Cip1 protein were also observed in Adriamycin-treated cells after 6 h, suggesting that the regulation of p53 by Survivin is functional (Figure 3b ).
P53 mRNA was reduced at the end of the transfection period ( Figure 4a overexpressing Survivin, while elevated p53 mRNA was observed in cells expressing T34A Survivin, at least at 6 h post Adriamycin (Figure 4a ), suggesting an effect of Survivin on p53 mRNA. Recently, two homologues of p53, p63 and p73, were identified, and unlike p53, they each have two promoters, which can result in alternatively spliced mRNA. Protein isoforms containing transactivation domains (TAp63 and TAp73) transactivate a similar set of target genes as p53, while proteins lacking the TA domain (DNp63 and DNp73) can function as antagonists of p53 and the full-length TAp63 and TAp73 isoforms (Irwin and Kaelin, 2001; Yang et al., 1998 Yang et al., , 2002 . To investigate whether Survivin regulates p63 and p73 expression, specific primers were designed to differentially detect the alternatively spliced TAp63, DNp63, TAp73 and DNp73 mRNAs by RT-PCR and antibodies specific for the protein isoforms were used for Western analysis. Transient expression of wild-type Survivin resulted in elevated DNp63 and TAp73 mRNA both basally, that is, after 18 h transfection, and after 2 and 6 h treatment with Adriamycin ( Figure 4a ). Forced expression of T34A Survivin had the opposite effect on basal and Adriamycin-induced DNp63 and TAp73 mRNA. Survivin overexpression also resulted in elevated DNp73 mRNA; however, this was observed only at higher RT-PCR cycles (Figure 4b ), suggesting that the DNp73 mRNA transcript is expressed at low levels. This was confirmed by direct comparison to TAp73 mRNA (Figure 4c ). In addition to an increase in mRNA, DNp63 and TAp73 protein were also elevated in MCF7 cells overexpressing Survivin, both basally and after 6 h of treatment with Adriamycin (Figure 4d ), while forced expression of T34A Survivin had the opposite effect on both basal and Adriamycin-induced DNp63 and TAp73 protein (not shown). We did not detect TAp63 mRNA in MCF7 cells, even at high RT-PCR cycles (450).
Survivin increases Mdm2 protein levels through caspase inhibition
Although experiments in which Survivin protein levels were modulated suggest that Survivin might affect p53 transcription, p53 is usually not regulated at the transcriptional level; rather, it is primarily regulated at the level of protein stability and function, particularly by Mdm2 (Haupt et al., 1997; Kubbutat et al., 1997) . We therefore evaluated whether the observed effects of Survivin on p53 could be mediated post-translationally through Mdm2. Transient expression of Survivin had a modest enhancing effect on Mdm2 protein after Adriamycin treatment (Figure 5a -left panel), while overexpressing either T34A or AS Survivin resulted in dramatically decreased Mdm2 protein (Figure 5a -left panel). In Adriamycin-treated BaF3 cells, ectopic Survivin had a more robust effect on enhancing Mdm2 protein, and similar to MCF7 cells, overexpression of T34A or AS Survivin dramatically reduced Mdm2 protein (Figure 5a -right panel) . None of the Survivin constructs had any effect on Mdm2 mRNA at 6 h post Adriamycin treatment when expressed in either MCF7 or BaF3 cells (Figure 5a ). However, these results seemed inconsistent with the effects of Survivin on p53 mRNA and protein described earlier and the known effect of p53 on induction of Mdm2 (Haupt et al., 1997; Kubbutat et al., 1997) . We therefore analysed Mdm2 mRNA in MCF7 cells transiently transfected with vector or wild-type Survivin immediately after transfection and at multiple time points post Adriamycin treatment ( Figure 5b ). Quantitative real-time RT-PCR demonstrated that Survivin expression dramatically reduces Mdm2 mRNA between 1 and 3 h post Adriamycin treatment that was normalized by 6 h, consistent with the 6-h post Adriamycin RT-PCR results shown in Figure 5a . Overall, these results strongly suggest that the effects of Survivin on Mdm2 were post-translational.
Since Mdm2 contains a caspase cleavage site (Chen et al., 1997; Erhardt et al., 1997) , we evaluated whether regulation of Mdm2 by Survivin results from caspase inhibition. In BaF3 cells, caspase-3 activation and the decrease in Mdm2 observed following Adriamycin treatment in cells expressing either T34A or AS Survivin were blocked by the caspase inhibitor Z-VAD-FMK, indicating that Mdm2 cleavage is regulated by Survivin through caspase inhibition (Figure 6a ). The increase in p53 normally observed in cells expressing T34A and AS Survivin was also blocked by Z-VAD-FMK, which is consistent with the effects of Survivin on Mdm2 and post-translational modulation of p53 protein.
It is known that Mdm2 functions as an ubiquitin E3 ligase and promotes p53 degradation by the ubiquitinproteosome (Honda et al., 1997) . We therefore added the proteosome inhibitor, ALLN to stably transduced BaF3 cells for 2 h, visualized p53 and p53 ubiquitin conjugates by Western blot analysis using anti-p53 antibody and used densitometry to quantitate p53 degradation. Compared to cells expressing empty vector, significantly more ubiquitin-conjugated p53 was seen in BaF3 cells overexpressing wild-type Survivin, while less ubiquitin-conjugated p53 was seen in cells expressing ectopic T34A or AS Survivin (Figure 6b ). These results provide strong support that modulation of Survivin protein level modulates p53 protein posttranslationally, and results from inhibition of caspasemediated Mdm2 cleavage.
Discussion
Regulation of apoptosis is balanced by signals that promote apoptosis such as p53 and caspases, and antiapoptotic factors, such as Mdm2 and Bcl-2, that inhibit p53-mediated apoptosis. Using stable and transient expression of wild-type Survivin or T34A and AS constructs that disrupt Survivin function or production (Grossman et al., 2001; Mesri et al., 2001; Fukuda et al., 2004) , we demonstrate the presence of a new regulatory pathway whereby Survivin regulates p53 function by inhibiting caspase-mediated cleavage of Mdm2. We also present new evidence for differential regulation of the p53 homologues p63 and p73 by Survivin, which may represent additional molecular pathways involved in the antiapoptotic and growthenhancing effects of this inhibitor of apoptosis.
Recent studies suggest that wild-type p53 can repress Survivin transcription (Hoffman et al., 2002; Mirza et al., 2002; Zhou et al., 2002) , although it is not clear whether p53 directly binds to a p53 response element in the Survivin promoter (Hoffman et al., 2002) or suppresses histone acetylation of the Survivin promoter without binding (Mirza et al., 2002) . We also observe a decrease in Survivin protein in Adriamycin-treated BaF3 cells coincident with p53 induction (Z Wang and LM Pelus, unpublished), which is consistent with Survivin as a target of p53 repression. However, our studies using Survivin overexpression or Survivin disruption point to a regulatory loop in which Survivin represses p53, which results in apoptotic blockade and continued cell growth, bypassing normal apoptosis and DNA repair control points. Our demonstration of p53 regulation by Survivin is supported by two recent reports which demonstrate that p53 is elevated upon conditional knockout of Survivin in double-negative thymocytes (Okada et al., 2004) or treatment of colorectal cancer cells with Survivin RNAi (Beltrami et al., 2004) . In the thymocyte system, the p53 pathway appears to be primarily involved in cell cycle arrest and control of cell cycle checkpoints, while in colorectal cancer cells the Survivin/p53 pathway is involved in blocking mitochondrial apoptosis, similar to our findings.
In transiently transfected MCF7 cells, ectopic Survivin reduces p53 mRNA and elevates DNp63, TAp73 and DNp73 mRNAs. This effect of Survivin on p53 family mRNA is surprising since transcriptional regulation is not a primary mechanism of p53 regulation (Levine and Momand, 1990; Perry and Levine, 1993) and Survivin does not contain a recognizable DNA-binding domain. Since our studies employed RT-PCR, they do not directly demonstrate an effect of Survivin at the level of transcription, which requires gene reporter and promoter activity assays. These experiments are not straightforward, given the need for cotransfection of Survivin and reporter systems in the face of endogenous Survivin levels in most cell systems. In this regard, preliminary experiments using transient transfection of Survivin and a p53 promoter-luciferase construct in MCF7 cells have not identified a significant effect of Survivin on p53 promoter activity. However, the Caenorhabditis elegans Survivin homologue BIR-1 regulates transcription without promoter binding through effects on histone phosphorylation (Kostrouchova et al., 2003) . It is possible that the effects of Survivin on p53 family mRNA could be mediated through a similar mechanism, or alternatively, through effects on mRNA stability, gene acetylation or through indirect effects with other transcriptional regulators. These mechanisms are currently under investigation.
Our studies on regulation of p53 function in Adriamycin-treated BaF3 and MCF7 cells demonstrate that ectopic Survivin results in significantly enhanced levels of Mdm2 protein that occur coincident with reduction in total and phosphorylated p53, despite a transient decrease in Mdm2 mRNA. We further demonstrated that the increase in Mdm2 protein was blocked by Survivin disruption and reversed by addition of a broad-spectrum caspase inhibitor to cells expressing T34A or AS Survivin. In addition, proteosome inhibition studies confirmed enhanced ubiquitination of p53 in cells expressing ectopic Survivin and reduced ubiquitination of p53 when the dominant-negative T34A or antisense Survivin constructs are expressed. Together, these results suggest a novel regulatory pathway whereby Survivin post-translationally increases Mdm2 protein and subsequently ubiquitination of p53, by blocking caspases that can cleave Mdm2 protein. These data are (Chen et al., 1997) and targeting p53 for degradation (Haupt et al., 1997; Kubbutat et al., 1997) and the fact that Mdm2 contains a caspase cleavage site (Chen et al., 1997; Erhardt et al., 1997) . In addition, Mdm2 has been shown to promote G 1 /S phase transition (Martin et al., 1995) , which is in good agreement with the demonstration by ourselves and others that Survivin increases S phase in primary hematopoietic cells (Fukuda et al., 2002) and hepatoma cells (Suzuki et al., 2000) . We have shown that ectopic Survivin affects mRNA and protein expression of the p53 homologues DNp63, TAp73 and DNp73 mRNA. DNp63 and DNp73, which lack transactivation domains, can act as dominantnegatives on p53 (Irwin and Kaelin, 2001; Yang et al., 2002) and elevation of DNp63 and DNp73 mRNA and/ or protein by Survivin may represent additional pathways involved in mediating its antiapoptotic effects. On the other hand, TAp73 mimics p53 activities, including apoptosis induction, cell cycle arrest and transactivation of similar target genes (Jost et al., 1997; Kaghad et al., 1997) , activities that are not consistent with the antiapoptotic effects of Survivin. One explanation for upregulation of TAp73 could be compensation to counterbalance p53 repression and induction of DNp63 and DNp73. However, recent data suggest that TAp73 can act as a dominant negative on p53 through repression of transcription of p21 WafÀ1/Cip1 (Novak et al., 2001; Freebern et al., 2003) . This suggests that upregulation of TAp73 by Survivin may in fact reinforce its antiapoptotic effects. In addition, TAp73 induction and p53 repression may explain the reduction of p21
WafÀ1/Cip1 in Adriamycin-treated BaF3 and MCF7 cells expressing ectopic Survivin. Although these results would seem inconsistent with our studies in hematopoietic cells from p21 normal and gene-deleted mice, which demonstrated a partial p21 requirement for Survivin's antiapoptotic activity (Fukuda et al., 2004) , p21 expression is also post-translationally regulated and its function is modified by phosphorylation (Zhou et al., 2001; Li et al., 2002) and/or subcellular localization and in a cell-type specific manner (Levkau et al., 1998; Asada et al., 1999) . In addition, p21 is a caspase substrate (Gervais et al., 1998; Levkau et al., 1998) . This suggests that although Survivin utilizes p21 to block apoptosis, it can repress p21 expression through p53 and regulate p21 stability post-translationally. These issues underscore the need to analyse transcriptional and post-translational modification of p21 to fully understand the Survivin/p53/p21 axis.
The fact that we did not detect TAp63 in our MCF7 cells does not mean that this isoform is not regulated by Survivin. A previous study by Waltermann et al. (2003) detected the mRNA for this isoform in MCF7 cells; however, it was less abundant than TAp73 and DNp63 transcripts, and similar in abundance to the DNp73 transcript, which we find to be expressed only at very low level in our MCF7 cells. Our lack of detection of TAp63 could relate to differences in primers used for RT-PCR, although our primers have previously been shown to detect TAp63 in normal and neoplastic tissues (Nylander et al., 2003) and detect TAp63 in plasmid cDNA and in MCF7 and TF1 cells after transfection. It is possible that differences in results may relate to MCF7 cells themselves. In this regard, Hall et al. (2000) were unable to detect TAp63 protein by Western blotting in their MCF-7 cells. Ultimately, complete understanding of p53 family regulation by Survivin will require analysis of the full complement of p63 and p73 isoforms and will require identification/construction of suitable cell models.
Materials and methods
Reagents and antibodies
Recombinant mouse (rm)IL-3 and rabbit anti-human Survivin antibody (AF886) were purchased from R&D Systems, Minneapolis, MN, USA. Antibodies recognizing pan-p53 (Ab-1), p63(Ab-1) and Mdm2(Ab-4) were from Oncogene Sciences, EMD Biosciences, La Jolla, CA, USA. Antibodies recognizing TAp73 and DNp73 were obtained from Dr B Vojtesek, Masaryk Cancer Institute, Brno, Czech Republic. Anti-DNp63 was provided by Dr Nylander, Umea˚University, Umea˚, Sweden. Antiactive caspase-3 was purchased from Calbiochem, EMD Biosciences. PE-conjugated antiactive caspase-3 was from BD Biosciences, Palo Alto, CA, USA. Anti-phospho-Ser 15 -p53 and goat antiactin antibodies were obtained from Santa Cruz Biotechnology, Santa Cruz, CA, USA. The caspase inhibitor (Z-VAD-FMK) was from Apotech, San Diego, CA, USA. Annexin V apoptosis detection kits were obtained from BD PharMingen, San Diego, CA, USA. The proteosome inhibitor ALLN, Propidium Iodide (PI) and Adriamycin were purchased from Sigma Chemicals, St Louis, MO, USA.
Retroviral transduction and generation of BaF3 cells expressing Survivin constructs
Construction of retrovirus containing wild-type and T34A mouse Survivin in the bicistronic IRES-EGFP-MIEG3 vector have been described previously (Fukuda et al., 2002) . Retrovirus containing human T34A or AS Survivin in IRES-EGFP-MIEG3 vector was generated by PCR based in vitro mutagenesis. The primers for T34A mutagenesis were 5 0 -phospho-CGTCCGCGTCGGGAGGTTCTT-3 0 and 5 0 -phosphoCGGGGCCTCGCCTACCGGCTC-3 0 . PCR was carried out for 30 cycles using wild-type human Survivin cDNA in the TOPO plasmid (Invitrogen) as a template. The resultant product was cloned into the MIEG3 vector as described (Fukuda et al., 2004) . Human AS Survivin represents Survivin cloned into the MIEG plasmid in the reverse orientation. Retrovirus transduction of MIEG constructs or vector backbone into BaF3 cells was carried out as described (Fukuda et al., 2002) , with minor modifications. Briefly, exponentially growing cells were incubated with freshly generated ecotropic virus supernates for 48 h in the presence of rmIL-3 on dishes precoated with recombinant fibronectin fragment CH296 (Takara Shuzo, Otsu, Japan). GFP Positive cells were isolated by FACS and expanded. BaF3 cells were maintained in RPMI-1640 medium containing 10% heat-inactivated fetal bovine serum (HI-FBS) (HyClone Sterile System, Logan, UT, USA) 1% penicillin-streptomycin and 0.1 ng/ml rmIL-3. MCF7 cells were maintained in RPMI-1640 containing 10% HI-FBS and 1% penicillin-streptomycin. Transient transfection of MCF7 using MIEG vectors containing Survivin cDNAs was carried out using Lipofectamine s (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Transfection efficiencies of Z30% were routinely observed by flow cytometry based on GFP expression.
RNA isolation and RT-PCR
Total RNA was harvested using the RNeasy kit (Qiagen, Valencia, CA, USA). RNA (1 mg) was reverse-transcribed with murine Moloney Leukemia Virus reverse transcriptase (Promega, Madison, WI, USA) and 10% of the complementary DNA used for RT-PCR. The primers used are shown in Table 2 . RT-PCR was performed with Pwo-polymerase (Roche Molecular Biochemicals, Indianapolis, IN, USA). Reactions were carried out for 25, 30 and 35 cycles consisting of 1 min denaturing at 951C, 1 min annealing at the temperatures listed in Table 2 , and 1 min elongation at 721C. The products were separated by electrophoresis in 2% agarose and visualized with ethidium bromide.
Quantitative real-time RT-PCR
Primers and probes for Mdm2 were designed using Primer Express Software (Applied Biosystems, Foster City, CA, USA) and purchased from Applied Biosystems. For Mdm2, the forward and reverse primers were 5 0 -AGCCCTCTTCCATC TCCTGTAGT-3 0 and 5 0 -TCAATCGGGATACTTCAGTTC GA-3 0 and the TaqMan probe was 5 0 -6FAM-TCGTCAGAT CCTGGAAGTGTCCCTGAC-TAMRA-3 0 . The GAPDH primers and probes were purchased from Applied Biosystems. Total RNA was treated with DNase (Promega, Madison, WI, USA) for 30 min at 371C and 10 ng of total RNA analysed by real-time RT-PCR as described previously (Fukuda et al., 2002) . Mdm2 and GAPDH PCR reactions were performed in separate wells in triplicate and the average threshold cycle (CT), representing the cycle at which a significant increase in fluorescence occurs, was used in subsequent calculations. The relative difference in Mdm2 mRNA was determined using the CT method as outlined in the Applied Biosystems protocol for RT-PCR. Briefly, a CT value for GAPDH was subtracted from the CT values for Mdm2 and converted to fold change compared to vector control transfected cells by raising 2 to the ÀCT power.
Western blot analysis
Cells were washed in PBS and lysed in buffer containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 10 mg/ml phenylmethyl sulfonyl fluoride and 1 mM sodium orthovanadate. Aliquots were kept on ice for 30 min and centrifuged at 14 000 g for 30 min and supernates used for Western blot. Protein concentration was determined using Bio-Rad protein assay kit, Bio-Rad Laboratories, Hercules, CA, USA. Protein aliquots were denatured in 2 Â SDS buffer at 951C for 5 min, separated on 10% SDSpolyacrylamide gels (SDS-PAGE) gels (Invitrogen) and transferred onto nitrocellulose membranes. The filters were incubated with specific antibodies followed by horseradish peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin and developed by means of electrogenerated chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Flow cytometry analysis for intracellular protein and apoptosis
For hypodiploid DNA analysis, cells were fixed in 70% ethanol overnight at 41C, washed with PBS and resuspended in PI buffer (50 mg/ml PI in PBS) for 30 min. For Annexin-V staining, cells were washed with PBS and stained with PE-Annexin-V according to the manufacturer's instructions. For intracellular staining for active caspase-3, cells were fixed in 4% paraformaldehyde, permeabilized with 0.25% Triton X-100/0.5% BSA in PBS and blocked with FcgIII/II for 10 min on ice. After washing, cells were stained with PE-conjugated anti-caspase-3 and analysed using a FACScan and CellQuest software (Becton Dickinson, San Jose, CA, USA). 
Statistical analysis
Statistical analysis of data was determined using the two-tailed t-test in Microsoft Excelt (Microsoft, Seattle, WA, USA).
